[CLSTR]
API
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 5 sources · 6 days · First seen · Last updated

Ultragenyx priority review voucher sales

Overview

Ultragenyx Pharmaceutical Inc. has entered into agreements to sell priority review vouchers (PRVs) earned through FDA approvals of gene therapies for rare pediatric diseases.

Initially, the company agreed to sell a single voucher for US$210 million, which was awarded following the accelerated approval of Genglycos for glycogen storage disease type Ia.

Subsequently, Ultragenyx expanded these efforts, securing agreements to sell two vouchers for a combined total of approximately $413 million. This includes the original $210 million voucher and a second voucher valued at $203 million, which was awarded following the mid-September approval of Fayuvi for Sanfilippo syndrome Type A. The company intends to use the non-dilutive capital from these sales to support its drug pipeline and path toward profitability.

Entities

USA Rare Earth Inc. · Fayuvi · Ultragenyx Pharmaceutical Inc. · Genglycos · FDA

Timeline

  1. [BUSINESS] 2 sources
    Ultragenyx to secure $413M through sale of two rare disease priority review vouchers

    Ultragenyx is set to receive approximately $413 million from the sale of two FDA priority review vouchers earned through the approval of new gene therapies for rare pediatric diseases.

  2. [BUSINESS] 3 sources
    Ultragenyx to sell rare disease priority review voucher for US$210M

    Ultragenyx Pharmaceutical will sell a rare pediatric disease priority review voucher for US$210 million to fund the development of therapies for rare diseases.

Sources

medcitynews.com · mugglehead.com · pharmexec.com · stocknews.com · xconomy.com